Inside Novonesis A/S's Push to Democratize Biomanufacturing & Bioprocess Synthetic Biology

Novonesis A/S has entered the synthetic biology platforms arena with Novonesis, a platform that the world's largest biosolutions company, engineering microorganisms and enzymes for every industry on earth. The move positions the company in a market projected to reach $3.4 billion by 2028, where 500+ engineered organisms are in commercial pipelines. Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen, creating the world's largest microbial and enzyme solutions company. The combined company engineers and produces a vast portfolio of industrial enzymes, microbial cultures, specialty fermentation ingredients, and biostimulants used in food production, agriculture, animal health, cleaning products, biofuels, and pharmaceutical manufacturing. For VP Strain Engineering and CTO professionals evaluating new solutions, the entry adds another option in an increasingly crowded field. The broader context is unmistakable: enterprises are moving beyond experimental AI pilots toward production-grade platforms that integrate with existing infrastructure and deliver measurable ROI from day one.

Core Synbio Technology

For VP Strain Engineering and CTO professionals, Novonesis addresses several critical needs. The platform's foundry-scale assembly capabilities — robotic dna assembly and transformation processing thousands of genetic designs in parallel — form the foundation. Layered on top, genetic parts catalog provides curated libraries of characterized genetic parts including promoters, terminators, and regulatory elements. Design-Build-Test-Learn Automation extends the platform further, automated dbtl cycle with integrated data capture and machine learning optimization. The platform's design reflects a market reality: 500+ engineered organisms are in commercial pipelines, and buyers want solutions that deliver quickly. Enterprise buyers in the synthetic biology platforms space increasingly evaluate platforms on three criteria: time-to-value, integration depth with existing systems, and the ability to demonstrate 5-10x faster design-build-test-learn cycles with AI-guided design in controlled pilots before committing to full-scale deployment.

On the integration front, Novonesis connects with KBase, DOE JGI, NCBI GenBank, Addgene and 11 additional systems. For synthetic biology platforms buyers, native connectivity to industry-standard platforms is often the deciding factor — and Novonesis A/S appears to understand this.

Industry Forces

Across the biomanufacturing & bioprocess sector, foundry-as-a-service models are democratizing synthetic biology. This isn't a future prediction — it's happening now. 500+ engineered organisms are in commercial pipelines, and the broader synthetic biology platforms market is on track to reach $3.4 billion by 2028. VP Strain Engineering and CTO professionals are responding by expanding their evaluation of AI-native platforms, seeking solutions that can deliver 5-10x faster design-build-test-learn cycles with AI-guided design without multi-year implementation timelines. The shift reflects a broader reckoning in the industry technology: the gap between AI-enabled operators and those still relying on rules-based systems is widening, and it's showing up in everything from customer satisfaction scores to operational cost ratios. For vendors like Novonesis A/S, this creates an opportunity — but also a demanding buyer who expects rapid time-to-value and seamless integration with existing technology stacks.

Enterprise Considerations

Enterprise buyers evaluating Novonesis should consider several practical factors. Implementation complexity varies significantly across synthetic biology platforms platforms, and VP Strain Engineering and CTO teams need to assess how the solution fits into their existing technology stack. Integration with incumbent systems — whether LIMS platforms, instrument control systems, or regulatory submission databases — often determines whether a pilot succeeds or stalls. Novonesis A/S will need to demonstrate that Novonesis can be deployed without disrupting ongoing biomanufacturing & bioprocess operations, particularly during critical experimental campaigns when system stability is critical.

Competitive Position

Novonesis A/S brings several things to the table: a focus on synthetic biology platforms, and the tailwinds of a $3.4 billion by 2028 market opportunity that is growing faster than most adjacent categories in AI technology. But it faces stiff competition from Ginkgo Bioworks Holdings, Inc., each with established customer bases and production track records that Novonesis A/S will need to match. The risk for buyers: newer platforms may lack the integration depth and battle-tested reliability that enterprise biomanufacturing & bioprocess operations demand, particularly during peak periods when system failures have outsized consequences. The upside: 5-10x faster design-build-test-learn cycles with AI-guided design for those who choose well. The smart approach for VP Strain Engineering and CTO teams is to run a structured pilot, benchmark against current systems, and make a data-driven decision rather than relying on vendor claims alone.